17722-52-0

Basic information

• Product Name: 4-[(4-CHLOROPHENYL)AMINO]-4-OXOBUTANOIC ACID
• Synonyms: OTAVA-BB BB0110420277;4-[(4-CHLOROPHENYL)AMINO]-4-OXOBUTANOIC ACID;IFLAB-BB F0358-0044;ASISCHEM D13214;AURORA 2782;BUTTPARK 41\07-63;4-[(4-chlorophenyl)amino]-4-keto-butyric acid;N-(4-Chloro-phenyl)-succinamic acid
• CAS NO: 17722-52-0
• Molecular Formula: C₁₀H₁₀ClNO₃
• Molecular Weight: 227.64
• Mol File: 17722-52-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 530.6 °C at 760 mmHg
• Flash Point: 274.7 °C
• Appearance: /
• Density: 1.346 g/cm³
• Vapor Pressure: 3.06E-10mmHg at 25°C
• Refractive Index: 1.61
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-[(4-CHLOROPHENYL)AMINO]-4-OXOBUTANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(4-CHLOROPHENYL)AMINO]-4-OXOBUTANOIC ACID(17722-52-0)
• EPA Substance Registry System: 4-[(4-CHLOROPHENYL)AMINO]-4-OXOBUTANOIC ACID(17722-52-0)

Safety Data

• Hazardous Substances Data: 17722-52-0(Hazardous Substances Data)

Usage

General Description

4-[(4-chlorophenyl)amino]-4-oxobutanoic acid, also known by its chemical formula C10H10ClNO3, is a compound with potential medicinal and pharmaceutical applications. It is a derivative of the amino acid phenylalanine and contains a chlorine atom. 4-[(4-CHLOROPHENYL)AMINO]-4-OXOBUTANOIC ACID has been studied for its potential use in the development of new drugs due to its ability to interact with biological systems. It has also been investigated for its potential anti-inflammatory and analgesic properties. Its structure and properties make it a promising candidate for further research and development in the field of pharmaceutical chemistry.

InChI:InChI=1/C10H10ClNO3/c11-7-1-3-8(4-2-7)12-9(13)5-6-10(14)15/h1-4H,5-6H2,(H,12,13)(H,14,15)

Upstream product

• 108-30-5 succinic acid anhydride 
• 106-47-8 4-chloro-aniline 
• 108-31-6 maleic anhydride 

Downstream Products

• 86396-55-6 4-<4-Chlor-anilino>-4-oxo-buttersaeure-methylester 
• 80452-55-7 7-chloro-1,3,4,5-tetrahydro-2H-1-benzazepine-2,5-dione 
• 6943-00-6 1-(4-chlorophenyl)pyrrolidine-2,5-dione 
• 1631-29-4 N-(4-chlorophenyl)maleimide 
• 1375737-04-4 N¹-(4-chlorophenyl)-N⁴-(3-(3-hydroxypiperidin-1-yl)propyl)succinamide 
• 1375737-07-7 N¹-(4-chlorophenyl)-N⁴-(1-morpholinobutan-2-yl)succinamide 
• 1375737-11-3 N¹-(4-chlorophenyl)-N⁴-(3-(2-isopropyl-1H-imidazol-1-yl)propyl)succinamide formate 
• 1375737-09-9 N¹-(4-chlorophenyl)-N⁴-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)succinamide formate 
• 1375737-13-5 N¹-(4-chlorophenyl)-N⁴-(3-(2-methyl-1H-imidazol-1-yl)propyl)succinamide formate 
• 1375737-02-2 N¹-(4-chlorophenyl)-N⁴-((5-(hydroxymethyl)-4-methylthiazol-2-yl)(pyrrolidin-2-yl)methyl)succinamide hydrochloride 
• 1375737-03-3 N¹-(4-chlorophenyl)-N⁴-(4-(morpholinosulfonyl)benzyl)succinamide 
• 1375737-06-6 N¹-(4-chlorophenyl)-N⁴-(2-(3-methylpiperidin-1-yl)benzyl)succinamide 
• 1375737-14-6 N¹-(4-chlorophenyl)-N⁴-(1-((2-methylimidazo[1,2-a]pyrimidin-3-yl)methyl)piperidin-4-yl)succinamide 
• 1376434-70-6 N₁-(4-chlorophenyl)-N₄-((5-(hydroxymethyl)-4-methylthiazol-2-yl)(piperidin-2-yl)methyl)succinamide hydrochloride 

Relevant articles and documents

Synthesis and comprehensive structural studies of a novel amide based carboxylic acid derivative: Non–covalent interactions

The presented work studies the geometric and electronic structures of the crystalline network of a novel amide based carboxylic acid derivative, N–[(4–chlorophenyl)]–4–oxo–4–[oxy] butane amide, C10H10NO3Cl (1), constructed

Identification of two arylimides as cholinesterase inhibitors and testing of propranolol addition on impaired rat memory

Alzheimer's disease (AD) is clearly linked to the decline of acetylcholine (ACh) effects in the brain. These effects are regulated by the hydrolytic action of acetylcholinesterase (AChE). Therefore, a central palliative treatment of AD is the administration of AChE inhibitors although additional mechanisms are currently described and tested for generating advantageous therapeutic strategies. In this work, we tested new arylamides and arylimides as potential inhibitors of AChE using in silico tools. Then, these compounds were tested in vitro, and two selected compounds, C7 and C8, as well as propranolol showed inhibition of AChE. In addition, they demonstrated an advantageous acute toxicity profile compared to that of galantamine as a reference AChE inhibitor. in vivo evaluation of memory performance enhancement was performed in an animal model of cognitive disturbance with each of these compounds and propranolol individually as well as each compound combined with propranolol. Memory improvement was observed in each case, but without a significant additive effect with the combinations.

A facile and green synthesis of N-substituted imides

Anhydrides 1, 6 and 10 have been reacted, independently, with aromatic primary amines 2 in solid phase by simple physical grinding of reactants with p-toluenesulphonicacid as a catalyst to yield corresponding open chain derivatives, monoacid monoamides3,7 and 11 respectively. The latter have each been transformed into the corresponding cyclic derivatives, i.e. imides 5, 9 and 13 respectively in solid phase by simple physical grinding of each with K 2CO3, alkylating agent and tetrabutylammoniumbromide as a catalyst with short reaction times. These cyclic imides can also be obtained by physical grinding of each of 3, 7 and 11 with dicyclohexylcarbodimide as a dehydrating agent in solid phase.